---
title: "Larimar Therapeutics 2Q 2026: Net loss $32.8M, Diluted EPS $(0.30) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294814759.md"
description: "Larimar Therapeutics reported a Q2 2026 net loss of $32.8M and diluted EPS of $(0.30), widening from the prior year's $26.2M loss but improving per-share metrics. The company initiated a rolling BLA in June 2026, aiming for a mid-2027 launch. Key developments include FDA Breakthrough Therapy designation, completion of Phases 1–2, and ongoing Phase 3 planning. Increased R&D spending supported these regulatory and clinical milestones."
datetime: "2026-08-04T11:21:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294814759.md)
  - [en](https://longbridge.com/en/news/294814759.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294814759.md)
generator: "portal-rs"
---

# Larimar Therapeutics 2Q 2026: Net loss $32.8M, Diluted EPS $(0.30) — 10-Q Summary

Larimar Therapeutics reported results for the second quarter of 2026, posting a net loss of $32.8M and a common diluted net loss per share of $0.3, compared with a net loss of $26.2M and diluted net loss per share of $0.41 in the year‑ago quarter.

**Financial Highlights**

-   Net loss was $32.8M for 2Q 2026, versus a net loss of $26.2M in 2Q 2025 (loss widened by $6.6M YoY).
-   Common diluted net loss per share was $0.30 for 2Q 2026, versus $0.41 for 2Q 2025 (improved EPS loss YoY).
-   Six‑month results: Net loss was $62.4M for 1H 2026, versus a net loss of $55.5M for 1H 2025 (loss widened by $6.9M YoY).

**Business Highlights**

-   Regulatory progress: Received FDA Breakthrough Therapy designation and continued alignment with the agency on using skin FXN as a surrogate endpoint for an accelerated BLA.
-   Clinical milestones: Completed Phases 1–2; ongoing open‑label study with 43 patients dosed and over 10,000 doses administered; Phase 3 sites planned globally.
-   Safety and efficacy: Longer‑term tolerability observed, sustained increases in skin FXN and directional clinical benefit versus natural history (mFARS benefit of +2.6 at one year).
-   Commercial readiness: Rolling BLA initiated in June 2026 and commercial preparations scaled for a potential mid‑2027 launch.
-   R&D and operations: Increased R&D and G&A spending to support the BLA, manufacturing scale‑up, inspection readiness and Phase 3 initiation.

Original SEC Filing: Larimar Therapeutics, Inc. \[ LRMR \] - 10-Q - Aug. 04, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [LRMR.US](https://longbridge.com/en/quote/LRMR.US.md)

## Related News & Research

- [Larimar Therapeutics Q2 net loss widens to $32.78 million; R&D expenses rise to $28 million](https://longbridge.com/en/news/294812276.md)
- [Quanta Services announces dividend of R$ 0.03 per unit for Q3 2026](https://longbridge.com/en/news/297931955.md)
- [Marisa updates financial events calendar for 2026](https://longbridge.com/en/news/297913424.md)
- [Igua Sergipe board signs off Q2 2026 financial results](https://longbridge.com/en/news/297932404.md)
- [LyondellBasell announces dividend of R$ 1.72 per unit for 3Q 2026](https://longbridge.com/en/news/297814383.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**